Epalrestat for Diabetic Peripheral Neuropathy
Author Information
Author(s): Hotta N, Kawamori R, Atsumi Y, Baba M, Kishikawa H, Nakamura J, Oikawa S, Yamada N, Yasuda H, Shigeta Y, The ADCT Study Group
Primary Institution: Chubu Rosai Hospital
Hypothesis
The long-term efficacy of epalrestat in improving subjective symptoms and nerve function in patients with diabetic peripheral neuropathy was assessed.
Conclusion
Epalrestat provides a clinically significant means of preventing and treating diabetic neuropathy if used in appropriate patients.
Supporting Evidence
- Epalrestat showed better efficacy in patients with good glycaemic control.
- In the control group, no improvement in nerve function was observed.
- The odds ratio for the efficacy of epalrestat was approximately 2:1 compared to control subjects.
Takeaway
Epalrestat can help people with diabetes feel better and improve their nerve function if they are in good health.
Methodology
Data from the Aldose Reductase Inhibitor—Diabetes Complications Trial (ADCT) were analyzed, including longitudinal data on HbA1c and subjective symptoms over 3 years.
Potential Biases
Potential bias due to the open-label trial design, although some measures were taken to minimize it.
Limitations
The study design was open-label, which may introduce bias.
Participant Demographics
Patients with diabetic peripheral neuropathy, median motor nerve conduction velocity ≥ 40 m/s, and HbA1c ≤ 9.0%.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI 1.32–2.75
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website